XCOPRI
As listed in the register: XCOPRI
200 mg · tablet
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Cenobamate
- Made by
- Knight Therapeutics Inc.
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Xcopri). It describes the substance, not this exact product.
The precise mechanism by which cenobamate exerts its therapeutic effects in patients with partial-onset seizures is unknown.
Cenobamate has been demonstrated to reduce repetitive neuronal firing by inhibiting voltage-gated sodium currents.
Cenobamate is extensively metabolized.
Unchanged cenobamate accounted for 6.8% of the dose which was mainly excreted in the urine (6.4%).
Effect of Food No clinically significant differences in cenobamate pharmacokinetics were observed following administration of a high-fat meal (800 -1000 calories with 50% fat).
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-08-25
Safety of the active substance
From the US prescribing label for the same active substance (Xcopri). It describes the substance, not this exact product.
- XCOPRI is contraindicated in patients with: Hypersensitivity to cenobamate or any of the inactive ingredients in XCOPRI [see Warnings and Precautions ( 5.1 ) and Description ( 11 )] Familial Short QT syndrome [see Warnings and Precautions ( 5.2 )] Hypersensitivity to cenobamate or any of the inactive ingredients in XCOPRI.
- ( 4 ) Familial Short QT syndrome.
The most common adverse reactions that occurred in XCOPRI-treated patients (incidence at least 10% and greater than placebo) were somnolence, dizziness, fatigue, diplopia, and headache.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
European UnionNo exact match for this strength and form
Spain1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Knight Therapeutics Inc. |
|---|---|
| Active substance | Cenobamate |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 200 mg |
| Form | tablet |
| Classification | N03AX25 · Pain, sleep, mood, epilepsy and the brain |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02538768 |
| DPD drug code | 102745 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
11 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet6 products
- tablet, kit4 products
- 12.5 mg + 25 mg
- 100 mg + 150 mg
150 mg + 200 mg2
150 mg + 200 mg · 2 companies
- kit, tablet1 products
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.